Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Caribou Biosciences has raised $125.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2023.
Caribou Biosciences's investors include AbbVie, Janus Henderson Investors, Pfizer, Anterra Capital, Novartis.
Caribou Biosciences is headquartered in Berkeley, United States.
Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Caribou Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Caribou Biosciences — Funding & Investors." VCBacked, July 13, 2023, https://www.vcbacked.co/company/caribou-biosciences. Accessed August 14, 2026.
VCBacked. (2023). Caribou Biosciences — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/caribou-biosciences
{{cite web |title=Caribou Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/caribou-biosciences |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated